Muneer A. Satter Purchases 100,000 Shares of Vital Therapies, Inc. (VTL) Stock
Vital Therapies, Inc. (NASDAQ:VTL) Director Muneer A. Satter bought 100,000 shares of the stock in a transaction on Wednesday, December 13th. The shares were bought at an average price of $5.48 per share, with a total value of $548,000.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.
Vital Therapies, Inc. (NASDAQ:VTL) opened at $5.55 on Friday. Vital Therapies, Inc. has a 12-month low of $2.25 and a 12-month high of $6.50.
Vital Therapies (NASDAQ:VTL) last issued its quarterly earnings results on Wednesday, October 25th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.02. During the same period last year, the company earned ($0.32) EPS. research analysts anticipate that Vital Therapies, Inc. will post -1.26 EPS for the current year.
VTL has been the subject of a number of analyst reports. Zacks Investment Research lowered Vital Therapies from a “hold” rating to a “sell” rating in a report on Thursday, October 5th. BidaskClub upgraded Vital Therapies from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 5th. ValuEngine upgraded Vital Therapies from a “strong sell” rating to a “sell” rating in a report on Saturday, October 21st. Finally, Raymond James Financial restated a “buy” rating on shares of Vital Therapies in a report on Tuesday, December 5th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $8.00.
About Vital Therapies
Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.
Receive News & Stock Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related stocks with our FREE daily email newsletter.